建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
Announcement by Oneness on Nanchou Manufacturing Site Receiving GMP Certification from TFDA on Manufacturing Active Pharmaceutical Ingredient
Time Adjustment on Oneness Bio's Oral Presentation Time Slot at EWMA 2020 Online Conference
Oral presentation by Oneness Biotech at EWMA 2020 virtual conference on ON101 global Phase 3 MRCT results.
Oneness submits an IND to TFDA on a phase II clinical trial of FB704A, a mAb developed from its own platform, for treating severe neutrophilic asthma.
Oneness Biotech Co., LTD. receives a Mexican patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
The latest release of MSCI Taiwan Small Cap Index
Oneness Biotech Co., LTD. receives a Mexican patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
Oneness Biotech will proceed to unblind Phase 3 data of ON101 MRCT (protocol#ON101CLCT02) according to TFDA notification letter# 1096013906
Oneness Biotech receives upfront payment of US$14.48M from LEO Pharma A/S
Oneness Biotech receives an upfront payment of US$4M from a global pharma company.
Oneness Biotech, jointly with affiliate company, Microbio (Shanghai), signs a collaboration memorandum with global pharma company.
Oneness Biotech has been invited for oral presentation at the 38th Healthcare Conference organized by J.P. Morgan
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?